Stay up to date with our latest news and events.
The Michael J. Fox Foundation will be presenting a poster at this year’s conference describing the research tools program: The Michael J. Fox Foundation's Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology
Proteos will be exhibiting at Neuroscience 2016. Please stop by booth 4304 to meet us and learn why we are an industry leader in the production of recombinant proteins and antibodies.
Celebrating over 30,000 attendees from over 80 countries, the Society for Neuroscience's (SfN) annual meeting is the world's premier destination for anyone seeking ideas and tools related to the field. With members able to view more than 15,000 abstracts, explore countless exhibits and network with other professionals in the field, the meeting aims to assist neuroscience professionals at all stages of their careers.
The Michael J. Fox Foundation (MJFF) first goal is to propel breakthroughs that Parkinson's sufferers can immediately feel in their day to day lives. The foundation realizes the importance of protein reagents in many applications related to treating Parkinson's disease. MJFF has partnered with Proteos who provides them with the best quality reagents to support research of Parkinson's disease.
Proteos will be attending the 5th annual Grand Challenges in Parkinson’s Disease scientific symposium at the Van Andel Research Institute in Grand Rapids, MI from September 26-27, 2016. Please stop by our booth to learn more about Proteos.
Now available from the MJFF Research Tools Program is a conformation-specific rabbit monoclonal antibody raised against filament alpha-synuclein, which recognizes both oligomeric and filamentous alpha-synuclein. This project was done in partnership with Proteos, Inc.; Abcam; and Aarhus University.
New Alpha-synuclein Proteins Available
MJFF announced the commercial launch of human alpha-synuclein proteins including monomeric and filament versions, as well as protocols and specially formulated monomeric alpha-synuclein to generate pre-formed fibrils. This project was in partnership with Proteos, Inc., and the proteins were validated by the Jensen and Luk laboratories at Aarhus University and the University of Pennsylvania, respectively.
